Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human Phase I clinical trial of AVA3996

Next Previous
Trial Profile

A first-in-human Phase I clinical trial of AVA3996

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVA 3996 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man

Most Recent Events

  • 17 Apr 2023 According to an Avacta media release, the company plans a submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.
  • 23 Jan 2022 New trial record
  • 18 Jan 2022 According to an Avacta media release, the company plans a Clinical Trial Authorisation (CTA) and/or Investigational New Drug (IND) filing in the first half of 2023 and dosing of the first patient in this study later in the year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top